Mobile

A trial to evaluate the pharmacokinetics, safety, and tolerability of MK-7655A in children less than 18 years old with confirmed or suspected gram-negative infections

Update Il y a 4 ans
Reference: EUCTR2016-004328-43

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To obtain plasma PK data and characterize the PK profile of imipenem, cilastatin, and relebactam (REL) following administration of a single IV dose of IMI/REL in pediatric subjects from birth to less than 18 years of age receiving standard-of-care antibacterial therapy for a confirmed or suspected Gram-negative bacterial infection.

Inclusion criteria

  • Treatment of bacterial infections in pediatric populations

Links